News
Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma
Pfizer Inc. (NYSE:PFE) today announced safety and clinical response results from the ongoing Phase 1 study (NCT03269136) for PF-06863135, an investigational B-cell maturation antigen (BCMA)
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene
Agilent Presents Thought Leader Award to IIT Delhi Scientist Professor Anurag Rathore
Agilent Technologies Inc. (NYSE: A) has honored Prof. Anurag Rathore, a scientist at the Indian Institute of Technology (IIT) Delhi, with an Agilent Thought Leader Award, for his contributions to
Agilent Announces Alissa Interpret Selected by North West Genomic Laboratory Hub for Clinical Genomic Analysis
Agilent Technologies Inc. (NYSE: A) today announced its clinical informatics platform Alissa Interpret has been adopted by the North West Genomic Laboratory Hub (NW GLH) based in Manchester and
Agreement with Prime West Expands Humana’s Medicare Advantage Provider Network in Las Vegas and Henderson
Prime Accountable Care West, LLC (“Prime West”), a patient-centered, physician-led population health management company, and Humana Inc. (NYSE: HUM), a leading health and well-being company, have
St. Luke’s Health Partners and Humana Announce Value-Based Agreement in Idaho
St. Luke’s Health Partners and Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, are announcing a new value-based care agreement that will benefit Humana
Agilent Announces New, Innovative 7850 ICP-MS System
Agilent Technologies Inc. (NYSE: A) today announced a new ICP-MS instrument, the Agilent 7850 ICP-MS System, that provides new smart tools to minimize common time traps that can affect ICP-MS
Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for
Veeva Announces Fiscal 2021 Third Quarter Results
Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fiscal third quarter ended October 31, 2020.
Agilent Announces Launch of Global Biomarker Pathologist Training Program
Agilent Technologies Inc. (NYSE: A) today announced the launch of the Biomarker Pathologist Training Program, a global initiative created to empower pathologists to score biomarkers accurately and
Agilent Reports Fourth-Quarter and Fiscal Year 2020 Financial Results; Initiates Fiscal 2021 Guidance
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.48 billion for the fourth quarter ended Oct. 31, 2020, up 8% year over year (core(1) growth of 6%).
On a GAAP basis
Agilent Launches New NanoDis System for Nanoparticle Dissolution Testing
Agilent Technologies Inc. (NYSE: A) today announced the introduction of the NanoDis System for nanoparticle dissolution testing. Combining Agilent instrumentation and software to enable customers
Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA
Humana-Mays Healthcare Analytics 2020 Case Competition Winners Announced
The student team of Alexander Kondziolka and Jonathon Thierer from The Wharton School of the University of Pennsylvania has won the $40,000 First Place prize in the Humana-Mays Healthcare Analytics
Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine
Pfizer Inc. (NYSE:PFE) today announced results from the Phase 3 CROWN trial of LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with
Agilent Increases Cash Dividend to 19.4 Cents Per Share
Agilent Technologies, Inc. (NYSE: A) today announced that its board of directors has increased the company’s quarterly dividend to 19.4 cents per share of common stock. The dividend reflects an 8%
Humana and Vancouver Clinic Team Up in SW Washington to Provide Medicare Advantage Beneficiaries Access to Additional Neighborhood Clinic
Additional access to patient-focused primary care is coming to Clark County, Washington, thanks to Vancouver Clinic and Humana (NYSE: HUM), one of the nation’s leading health and well-being
Illumina to Webcast Upcoming Investor Conference Presentation
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.
Piper Sandler Annual
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine
Veeva Link wird auf 11 neue Behandlungsbereiche ausgeweitet
Veeva-Systeme (NYSE: VEEV) kündigte heute Veeva Link für 11 neue Behandlungsbereiche an, einschließlich bakterieller Infektionen, Kardiologie, Dermatologie, Endokrinologie, Gastroenterologie
Veeva Vault PromoMats unterstützt Bristol Myers Squibb bei der Beschleunigung von konformem Inhalts für das Markt-Engagement
Veeva Systems (NYSE: VEEV) gab heute bekannt, dass Bristol Myers Squibb (NYSE: BMY) Veeva Vault PromoMats einführt, um schnelle, konforme Inhalte über alle digitalen Kanäle zu liefern und so die
Humana Expands Medicare Advantage Offerings in Washington
Medicare beneficiaries in Benton, Walla Walla, and Franklin counties will now have more Medicare Advantage health plan coverage options during the 2021 Medicare Advantage and Prescription Drug Plan
Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise
Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion
Agilent Presents Thought Leader Award to Drs. Carl H. June and Michael Milone
Agilent Technologies Inc. (NYSE: A) today announced professors Carl H. June, MD, and Michael Milone, MD, Ph.D., as recipients of an Agilent Thought Leader Award. Both scientists are being